This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2022
  • /
  • 3
  • /
  • Filing of patent infringement suit by Ono Pharma a...
News

Filing of patent infringement suit by Ono Pharma against AstraZeneca K.K. relating to Imfinzi.

Read time: 1 mins
Published:2nd Mar 2022

Ono Pharmaceutical Co., Ltd. announced that it has filed a lawsuit for an injunction and damages (value of the subject matter of the suit is about 32 billion yen) against patent infringement, based on the patent on the anti-PD-L1 antibody owned by Ono (JP5885764; JP6258428), to the Tokyo District Court on February 28 against AstraZeneca K.K., which has been marketing Imfinzi (durvalumab).

Considering that the treatment is related to the life-saving of patients, Ono will not ask for a sales injunction of Imfinzi in this lawsuit, if Ono would make an agreement with AstraZeneca K.K. which will pay an appropriate consideration including royalties even outside the proceedings.

Condition: Non Small Cell Lung Cancer
Type: drug

EACCME® accredited eLearning

Doctor holding patient
Doctor holding patient
Learning Zone Homepage

Supportive care in oncology Learning Zone

Supportive care in oncology from a multidisciplinary team involves caring for patients with cancer, treatment adherence and adverse effect management.

Read more
150 mins
CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Latest drug news
Drug news
CHMP positive recommendation to change to marketing authorisation of Triumeq (abacavir sulfate / dolutegravir sodium / lamivudine) to treat HIV infections.-ViiV HealthCare

On 25 April 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Triumeq.

1 mins
Drug news
CHMP positive recommendation to change the marketing authorisation of Sirturo (bedaquiline) in patients with pulmonary tuberculosis.- Jansssen- Cilag (J&J)

On 25 April 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Sirturo (bedaquiline). The marketing authorisation holder for this medicinal product is Janssen-Cilag International NV.

1 min
Drug news
CHMP positive recommendation to extend the marketing authorisation of Alecensa (alectinib hydrochloride).- Roche.

On 25 April 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Alecensa.

1 min
See all news